Legumain is a promising target as it is expressed on CD206+/F4/80+ TAMs and a legumain-based DNA vaccine induced a robust CD8+ T cell response against TAMs in murine models of metastatic breast cancer, colon cancer and non-small cell lung cancer (189). This evidence concerns the gene LGMN and colonic neoplasm.